These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28758110)

  • 1. Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema.
    Shimizu N; Oshitari T; Tatsumi T; Takatsuna Y; Arai M; Sato E; Baba T; Yamamoto S
    Biomed Res Int; 2017; 2017():1747108. PubMed ID: 28758110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Functional and Morphological Prognosis After Intravitreal Injection Treatments According to Different Morphological Patterns of Diabetic Macular Edema in Real-Life: MARMASIA Study Group Report No.13.
    Limon DU; Kaplan FB; Saygın I; Önder Tokuç E; Kutlutürk Karagöz I; Kanar HS; Sevik MO; Yayla U; Çelik E; Sönmez A; Aykut A; Kumral Türkseven E; Erçalık NY; Oncu Aydın Ö; Bozkurt E; Aydoğan T; Emengen EB; Özkaya A; Açıkalın Öncel B; Yenerel NM; Şahin Ö; Karabaş L
    Semin Ophthalmol; 2024 Aug; 39(6):460-467. PubMed ID: 39087722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Effects of Switching to Faricimab in Eyes with Diabetic Macular Edema Refractory to Aflibercept.
    Tatsumi T; Kaiho T; Iwase T; Miura G; Shimizu D; Niizawa T; Ozawa Y; Arai M; Oshitari T; Takatsuna Y; Baba T
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792915
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of different anti-vascular endothelial growth factor agents, and dexamethasone implant therapy in patients with serous retinal detachment caused by Irvine-Gass syndrome.
    Karasu B; Kesim E; Celebi ARC
    Eur J Ophthalmol; 2024 Mar; 34(2):510-523. PubMed ID: 37408434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept vs. dexamethasone implant for recalcitrant diabetic macular edema in pseudophakic eyes - 1-year outcomes from a quazi-randomized study in India.
    Chakraborty D; Mondal S; Sengupta S; Maiti A; Boral S; Das A; Sinha TK; Nandi K
    Indian J Ophthalmol; 2024 Jul; 72(7):1001-1006. PubMed ID: 38622856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy.
    Toto L; Evangelista F; Viggiano P; Erroi E; D'Onofrio G; Libertini D; Porreca A; D'Aloisio R; Mariacristina P; Di Antonio L; Di Nicola M; Mastropasqua R
    Biomed Res Int; 2020; 2020():9496242. PubMed ID: 32104710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation.
    Wang XN; Cai X; He S; Zhang X; Wu Q
    Int Ophthalmol; 2023 Dec; 43(12):4399-4407. PubMed ID: 33783677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema.
    Saima Y; Yokota H; Kushiyama A; Hanaguri J; Ohno A; Takase K; Sugiyama R; Muranaka K; Yamagami S; Nagaoka T
    Sci Rep; 2024 Jun; 14(1):13798. PubMed ID: 38877041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis.
    Sun Z; Yang Y; Lin B; Huang Y; Zhou R; Yang C; Li Y; Huang S; Liu X
    BMC Ophthalmol; 2023 Nov; 23(1):473. PubMed ID: 37990182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab.
    Xing P; Meng B; Hu X; Qu W; Wang S
    Clin Ophthalmol; 2023; 17():3491-3497. PubMed ID: 38026602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab.
    Özata K; Atum M; Çelik E; Doğan E; Alagöz G
    J Curr Ophthalmol; 2019 Sep; 31(3):281-286. PubMed ID: 31528762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different approaches for treating myopic choroidal neovascularization: a network Meta-analysis.
    Wu YJ; Feng YL; Yang JS; Fan H; Li WS
    Int J Ophthalmol; 2023; 16(12):2105-2116. PubMed ID: 38111927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized versus non-vitrectomized eyes: a Meta-analysis.
    Wang YH; Xu Q; Luan J
    Int J Ophthalmol; 2024; 17(4):729-735. PubMed ID: 38638245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
    Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
    Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.
    Herbaut A; Fajnkuchen F; Qu-Knafo L; Nghiem-Buffet S; Bodaghi B; Giocanti-Auregan A
    J Ophthalmol; 2017; 2017():8035013. PubMed ID: 28900543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study.
    Vaze A; Nguyen V; Daien V; Arnold JJ; Young SH; Cheung CM; Lamoureux E; Bhargava M; Barthelmes D; Gillies MC;
    Retina; 2018 Oct; 38(10):1954-1961. PubMed ID: 28820848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.